Astec LifeSciences Limited Overview
Astec LifeSciences is a small-cap, B2B-only Indian manufacturer of off-patent agrochemical active ingredients (technicals), intermediates and select formulations, and a contract development and manufacturing (CDMO) partner to multinational crop-science and specialty-chemical innovators. Its historical franchise is triazole fungicides — tebuconazole, propiconazole, hexaconazole and related molecules — produced at five plants in MIDC Mahad, Maharashtra. Since Godrej Agrovet took control in 2015, Astec has been repositioned toward higher-value CDMO work and herbicide chemistry, supported by a dedicated R&D centre at Rabale (2023). The 2023–2025 global agrochemical destocking and Chinese generic oversupply hit Astec unusually hard: revenue fell from ₹677 crore (FY22) to ₹381 crore (FY25) and the company has posted three consecutive annual losses. FY26 marked an inflection, with revenue up 17.5%, EBITDA breakeven, and a ₹249 crore rights issue. Its investment case now rests on CDMO ramp-up, operating leverage, and Godrej parentage.
Company's own description. In its recurring "About" boilerplate across FY25–FY27 press releases, Astec describes itself as incorporated in 1994 and engaged in manufacturing agrochemical active ingredients (technical), bulk formulations and intermediate products, with a balanced mix of exports and domestic sales, exporting to over 18 countries (2026 releases; earlier materials cited approximately 24 countries). Its January 2026 PR Newswire release positions it as a manufacturer of agrochemicals, active ingredients and pharmaceutical intermediates with flexible reactor capacities of 3 KL to 32 KL across glass-lined, stainless steel and Hastelloy systems.
What the company does. Astec runs multi-step organic synthesis in batch reactors to produce (a) technical-grade active ingredients sold to formulators and agrochemical majors (the "Enterprise" business), and (b) custom-synthesised intermediates, active ingredients and specialty chemicals manufactured to customer specifications under contract (the "Contract Manufacturing & New Products" / CDMO business). ICRA's March 2026 rationale summarises the split as technical-grade fungicides and agrochemicals in Enterprise, and agrochemical intermediates and specialty chemicals in CDMO.
Business model and revenue model. Astec's revenue is almost entirely product revenue from B2B sales; there is no subscription, licensing or royalty income disclosed. Within product revenue, two economic models coexist:
Shares derived from company segment disclosures; company/AR-based summaries report 48% Enterprise / 52% CDMO for FY26.
Value chain position. Astec sits in the upstream manufacturing tier of the crop-protection value chain: it buys key starting materials and intermediates (50–55% of raw materials imported, primarily from China, per ICRA), performs synthesis to technical grade, and sells to formulators, distributors and innovators who brand and distribute to farmers. Some backward integration into intermediates partially hedges input cost volatility. It does not operate a farmer-facing branded formulation franchise; that role within the Godrej group sits with Godrej Agrovet's crop protection business, which is also a related-party customer/supplier.
Customer types. Large agrochemical MNCs (domestic subsidiaries and overseas), Indian formulators, innovator crop-science companies (CDMO), and group companies (GAVL, GIL). Historical disclosures cite Syngenta India and Nufarm as early customers (2009) and custom-synthesis clients in Europe, Japan and the US. Specific current customer names and concentration percentages are not publicly disclosed.
End-markets. Crop protection (fungicides dominant; herbicides growing; plant-growth regulators), household insecticides (transfluthrin), and life-science/specialty intermediates via CDMO.
Independent characterisation. Astec is best understood as a sub-scale, single-site specialty chemical manufacturer that was built on a narrow, commoditising triazole portfolio and is now mid-way through a deliberate pivot to CDMO. The pivot is strategically sound — CDMO revenue has greater customer stickiness and pricing insulation — but it is capital-intensive, slow to ramp and lumpy, as evidenced by CDMO revenue swinging from ₹13.6 crore (Q2 FY26, derived) to ₹77.6 crore (Q3 FY26) within one quarter. The business carries structurally high working capital (cash conversion cycle of 263 days in FY26 per Screener), leaving it dependent on parent support and short-term debt markets during the downturn.
Strategy
Stated strategic themes (synthesised from management commentary, ICRA, and the April 2023 R&D centre launch, paraphrased):
-
Pivot to CDMO. Become a preferred, application-agnostic manufacturing partner for innovator companies and MNCs, raising the share of higher-margin, more predictable contract revenue. Management has been selective in onboarding projects, favouring high-margin opportunities even at the cost of near-term growth.
-
Portfolio diversification beyond triazoles. Herbicide manufacturing (since August 2021) and new products reduce dependence on a handful of generic fungicides.
-
R&D-led process optimisation. The Rabale centre focuses on new product generation, process optimisation, scale-up and lifecycle management, with an emphasis on green chemistry; process improvements are explicitly intended to support margin expansion.
-
Capital discipline. Capex pruned to ₹10–15 crore per annum over the medium term; focus on lifting utilisation of existing assets.
-
Balance-sheet repair. Equity infusion via rights issue; debt prepayment; liquidation of high-cost legacy inventory.
-
Manufacturing and ESG positioning for export customers. Promotion of safety, quality and sustainability credentials (e.g., ICSCE Dubai, January 2026).
Initiatives in the last 24 months
Medium-term financial targets / guidance. No quantitative medium-term targets (revenue, margin or ROCE) are publicly disclosed. The only forward-looking commentary is qualitative: the Chair expects the demand–supply imbalance that has persisted since 2023 to normalise over the medium term (July 2026); ICRA expects recovery momentum to sustain but margins to stay below historic levels.
Products & Services
Astec does not publish product-wise revenue, launch dates or pricing. The catalogue below is compiled from the company website (as summarised by Screener's key-points extract), ICRA, and historic disclosures. All sales are B2B; pricing model is negotiated per order/contract (not publicly disclosed).
Enterprise — Triazole and other fungicides (core franchise)
| Product | Class / use | Target customer | Notes |
|---|---|---|---|
| Tebuconazole | Triazole fungicide (cereals, fruits, vegetables) | Formulators, MNCs | Historically a flagship volume molecule |
| Propiconazole | Triazole fungicide (cereals, rice, turf) | Formulators, MNCs | Long-standing product |
| Hexaconazole | Triazole fungicide (rice sheath blight, plantation crops) | Domestic formulators | High domestic relevance; also made by peers (e.g., Rallis) |
| Difenoconazole | Triazole fungicide (broad-spectrum) | Formulators, MNCs | Higher-value triazole |
| Metconazole | Triazole fungicide / PGR effect | Export customers | Niche, higher complexity |
| Cyproconazole | Triazole fungicide | Export customers | — |
| Prothioconazole | Triazolinthione fungicide | Export customers | Among the larger global triazole markets |
| Flutriafol | Triazole fungicide | Export customers | — |
| Metalaxyl / Metalaxyl-M | Phenylamide fungicide (oomycetes) | Formulators | Non-triazole diversification |
Enterprise — Herbicides (diversification since 2021)
| Product | Class / use | Notes |
|---|---|---|
| Quizalofop | Aryloxyphenoxy-propionate (grass weeds in broadleaf crops) | Produced in high-potency herbicide facility (commissioned Aug 2021) |
| Imazethapyr | Imidazolinone (soybean, pulses) | — |
| Sulfonylurea herbicides (unspecified) | ALS inhibitors, low-dose high-potency | Specific molecules not publicly disclosed |
Enterprise — Other actives
| Product | Class / use | Notes |
|---|---|---|
| Paclobutrazol | Plant growth regulator (triazole chemistry; mango flowering, fruit crops) | Shares triazole synthesis know-how |
| Transfluthrin | Pyrethroid household insecticide AI (vaporisers, coils) | Serves consumer-products customers; Godrej group adjacency |
| Intermediates | Triazole and other intermediates | Sold externally and used captively |
CDMO — Contract Development and Manufacturing Operations
| Service element | Description |
|---|---|
| Process development | Route scouting and optimisation at the Rabale R&D centre |
| Analytical and safety studies | Method development, process safety/hazard assessments |
| Pilot scale-up | Kilo-lab to pilot campaigns |
| Qualification samples | Customer validation batches |
| Plant design | Dedicated or adapted plant configuration |
| Commercial manufacture | Starting materials, active ingredients and advanced intermediates for crop-science, life-science and consumer-product customers |
| Asset base | Reactors of 3 KL–32 KL in glass-lined, SS and Hastelloy; two herbicide plants, one dedicated to CDMO |
Named CDMO molecules and customers are confidential (not publicly disclosed). Historical milestones include the commercialisation of two new CMO products and a new production process for an Enterprise product in FY22.
As a B2B technical manufacturer, Astec does not operate farmer-facing brands.
Financial Narrative
Source: consolidated audited financials as compiled by Screener.in (FY22–FY26), cross-checked with company press releases and ICRA. Ratios marked "derived" are computed by the analyst from these figures.
Income statement
Gross profit is not publicly disclosed on a consistent basis in sources reviewed. FY25 and FY26 company-reported EBITDA are −₹60.6 crore and +₹0.5 crore respectively; the minor differences from the derived row reflect rounding and forex-gain classification. Diluted EPS equals basic for practical purposes (ESOP dilution immaterial; diluted figures not separately captured).
Revenue CAGR FY22–FY26: −9.8% (derived). Over 10 years Screener reports a +7% sales CAGR; over 5 years, −4%.
Dividends per share. No dividend was paid for FY24, FY25 or FY26 (payout 0%).
Commentary. The P&L tells a three-act story. Act one (FY22): peak revenue of ₹677 crore with a 23% operating margin, fuelled by the post-COVID agrochemical upcycle and tight Chinese supply. Act two (FY23–FY25): a collapse driven by global channel destocking, Chinese generic capacity flooding triazole markets, and erratic monsoons. Revenue fell 44% from peak to FY25, and operating leverage worked brutally in reverse — Astec's fixed-cost base (depreciation up from ₹34 crore to ₹44 crore after capex for herbicide plants and the R&D centre; finance costs quadrupling from ₹9 crore to ₹37 crore) turned a modest revenue decline into a net loss of ₹135 crore in FY25. FY25 also absorbed high-cost legacy inventory, with an ₹18.5 crore write-down in Q1 FY25 alone. Act three (FY26): revenue recovered 17.5% to ₹448 crore on volume gains in both categories, EBITDA returned to breakeven, and the net loss narrowed to ₹81 crore. The H2 FY26 run-rate was markedly better: Q3 and Q4 FY26 EBITDA of ₹4.8 crore and ₹11.8 crore. Q1 FY27 (₹84.3 crore income, EBITDA ₹0.1 crore, loss ₹18.7 crore vs ₹33.0 crore) confirms seasonal weakness persists but at structurally lower losses.
Quarterly trajectory
Q2 FY26 EBITDA derived as 9M FY26 EBITDA loss of ₹11.2 crore less Q1 and Q3 values. Q1 FY25 PAT per Simply Wall St (₹397.2 million loss); other values from company releases and Screener.
Balance sheet
Cash balances are minimal: ₹27.05 million at FY25 (Simply Wall St) and ~₹10 crore at 30 Sep 2025 (ICRA). Net debt therefore approximates total borrowings. Short-/long-term debt split, goodwill/intangibles and working capital in absolute terms were not publicly disclosed in sources reviewed. ICRA-rated instruments at Mar 2026: fund-based working capital ₹283 crore, term loan ₹100 crore (maturity 30 Apr 2028), NCD ₹49 crore, CP programme ₹300 crore (₹100 crore outstanding at rationale date), non-fund-based ₹335 crore.
Commentary. The balance sheet absorbed the downturn through debt. Borrowings rose from ₹279 crore (FY22) to ₹555 crore (FY25) as negative operating cash flow coincided with a ₹350+ crore capex cycle (FY22–FY24). Net worth fell from ₹420 crore (FY23) to ₹235 crore (FY25) — a 44% erosion — pushing debt/equity to 2.36x. The July 2025 rights issue reset the capital structure: FY26 net worth recovered to ₹391 crore, and ~₹102 crore of term debt was prepaid from rights proceeds, bringing borrowings to ₹449 crore and debt/equity to 1.15x. The completion of the capex cycle is visible in CWIP falling from ₹165 crore (FY24) to ₹20 crore (FY26).
Cash flow
Capex derived as CFO minus FCF (Screener). Dividends paid for FY22–FY23 not separately captured (small amounts).
Commentary. Astec has generated negative free cash flow in every one of the last five years, cumulatively −₹357 crore. FY26 is notable: despite EBITDA breakeven, operating cash flow was −₹81 crore because revenue recovery was back-ended (Q4 FY26 was the largest quarter) and receivables surged (debtor days rose to 202 per Screener). This is a key watch item: the rights issue funded debt reduction, but the working-capital build consumed liquidity. Management has guided capex down to ₹10–15 crore per year (per ICRA), so FCF should approach operating cash flow in FY27.
Ratios
Net debt/EBITDA not meaningful for FY24–FY26 (EBITDA ≈ zero or negative). Interest coverage from Value Research; company-reported Interest Service Coverage Ratio was −1.48x (FY25) and −0.04x (FY26). Debtors turnover discrepancy: company results show 2.35x (FY25) and 2.25x (FY26), while the FY25 Annual Report table shows 3.14x (FY25) and 2.83x (FY24), likely reflecting standalone vs consolidated or different averaging methods.
Commentary. Every return metric peaked in FY22 and troughed in FY25. The single most important operational improvement in FY26 was inventory: inventory turnover improved from 1.30x (FY24) to 3.01x (FY26) as legacy high-cost stock was liquidated — ICRA explicitly credits this for part of the margin recovery. The offsetting deterioration was receivables, with debtor days jumping to 202, pushing the cash conversion cycle to a five-year high of 263 days. Current ratio below 1.0x reflects reliance on short-term instruments (CP, working-capital lines) to fund long-gestation assets.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment (INR Cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
Enterprise revenue | — | 175.4 | 210.2 |
CDMO / Contract Manufacturing & New Products revenue | — | 205.9 | 237.9 |
Total revenue from operations | 458.2 | 381.3 | 448.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%) and Segment Margins & Growth (%)
| Segment metric | FY25 | FY26 |
|---|---|---|
Enterprise share of revenue (%) | 46 | 47 |
CDMO share of revenue (%) | 54 | 53 |
Enterprise YoY growth (%) | — | 19.8 |
CDMO YoY growth (%) | — | 15.5 |
Revenue by Segment (Quarterly)
| Segment (INR Cr) | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Enterprise | 36.5 | 60.1 | 46.6 | 67.0 | 51.8 |
CDMO & New Products | 54.6 | 13.6 | 77.6 | 91.6 | 31.8 |
Total | 91.1 | 73.7 | 124.2 | 158.6 | 83.6 |
Income Statement and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 677 | 628 | 458 | 381 | 448 |
Total operating expenses | 522 | 551 | 464 | 448 | 453 |
Operating profit before other income (EBITDA ex-OI) | 154 | 77 | -6 | -66 | -4 |
Other income | 10 | 13 | 6 | 6 | 3 |
EBITDA incl. other income (company basis) | 164 | 90 | -1 | -61 | 1 |
Depreciation and amortisation | 34 | 34 | 36 | 44 | 45 |
Operating income / EBIT (derived) | 130 | 56 | -37 | -104 | -46 |
Finance costs | 9 | 21 | 25 | 37 | 35 |
Profit before tax | 121 | 35 | -62 | -141 | -81 |
Net income (PAT) | 90 | 26 | -47 | -135 | -81 |
EPS basic (INR) | 40.12 | 11.41 | -20.95 | -60.16 | -36.32 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 22.0 | -7.2 | -27.1 | -16.8 | 17.5 |
EBITDA margin ex-OI (%) | 23.0 | 12.0 | -1.3 | -17.0 | -1.0 |
EBIT margin (%) | 19.2 | 8.9 | -8.1 | -27.3 | -10.3 |
Pre-tax margin (%) | 17.9 | 5.6 | -13.5 | -37.0 | -18.1 |
Net margin (%) | 13.3 | 4.1 | -10.3 | -35.4 | -18.1 |
Effective tax rate (%) | 26 | 27 | -24 | -4 | 0 |
Financial Analysis
| Metric (₹ per share) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Dividend per share | 0 | 0 | 0 |
Income Statement
| Metric (INR Cr) | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue from operations | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 |
Total income | 70.3 | 100.5 | 95.8 | 120.3 | 91.6 | 74.8 | 125.5 | 161.3 | 84.3 |
Company-reported EBITDA | -45.3 | -17.7 | -3.8 | 6.3 | -10.5 | -5.5 | 4.8 | 11.8 | 0.1 |
Net profit (PAT) | -39.7 | -38.6 | -40.4 | -16.1 | -33.0 | -24.4 | -15.7 | -7.7 | -18.7 |
Balance Sheet
| Metric (INR Cr, at 31 March) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 897 | 979 | 975 | 881 | 942 |
Net fixed assets | 340 | 318 | 386 | 499 | 459 |
Capital work-in-progress | 23 | 127 | 165 | 21 | 20 |
Other (mainly current) assets | 534 | 534 | 424 | 361 | 463 |
Total borrowings | 279 | 341 | 494 | 555 | 449 |
Other liabilities | 221 | 219 | 112 | 92 | 102 |
Share capital | 20 | 20 | 20 | 20 | 22 |
Reserves | 377 | 400 | 350 | 215 | 368 |
Shareholders' equity (net worth) | 397 | 420 | 370 | 235 | 390 |
Key Financials
| Metric (INR Cr, at 31 March) | FY2025 |
|---|---|
Cash and equivalents (INR Cr) | 2.7 |
Net debt (INR Cr) | 552 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 24 | 75 | 10 | -8 | -81 |
Capital expenditure (derived) | 104 | 117 | 135 | 16 | 5 |
Free cash flow | -80 | -42 | -125 | -24 | -86 |
Investing cash flow | -104 | -113 | -135 | -15 | -4 |
Financing cash flow | 80 | 38 | 125 | 24 | 94 |
Dividends paid | — | — | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, derived on average equity) | 25.5 | 6.4 | -11.9 | -44.6 | -25.9 |
ROA (%, derived on average assets) | 11.4 | 2.8 | -4.8 | -14.5 | -8.9 |
ROCE / ROIC proxy (%, Screener) | 22 | 8 | -4 | -13 | -5 |
Current ratio (x) | — | 0.95 | 1.00 | 0.93 | 0.88 |
Debt / equity (x) | 0.70 | 0.81 | 1.34 | 2.36 | 1.15 |
Net debt / EBITDA (x) | 1.8 | 4.4 | — | — | — |
Interest coverage, EBIT basis (x) | 14.37 | 2.69 | -1.45 | -2.84 | -1.35 |
Asset turnover (x) | 0.85 | 0.66 | 0.47 | 0.42 | 0.49 |
Debtor days | 148 | 90 | 135 | 141 | 202 |
Inventory days | 176 | 268 | 224 | 196 | 169 |
Payable days | 179 | 161 | 102 | 100 | 107 |
Cash conversion cycle (days) | 145 | 197 | 256 | 237 | 263 |
Inventory turnover (x, company) | — | — | 1.30 | 2.14 | 3.01 |
Revenue by Region
| Region (INR Cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
Exports (outside India) | — | 259.9 | 277.4 |
Domestic (India) | — | 121.4 | 170.7 |
Total | 458.2 | 381.3 | 448.1 |
Revenue by Region (%) and Region Margins & Growth (%)
| Region metric (INR Cr) | FY25 | FY26 |
|---|---|---|
Exports share (%) | 68 | 62 |
Domestic share (%) | 32 | 38 |
Exports YoY growth (%) | — | 6.7 |
Domestic YoY growth (%) | — | 40.6 |
Revenue by Region (Quarterly)
| Region (INR Cr) | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|
Exports | 69.6 | 96.0 | 45.9 | 41.0 | 86.3 | 103.7 | 33.3 |
Domestic | 24.3 | 23.5 | 45.2 | 32.2 | 37.9 | 54.9 | 50.3 |
Valuation Snapshot
| Metric | Value |
|---|---|
Last close (16 Oct 2026) | ₹710 |
52-week high / low | ₹942 / ₹512 |
Market cap | ~₹1,583 crore |
Book value per share | ~₹175 |
Rights issue price (Jul 2025) | ₹890 |
2024 open offer price | ₹1,094.96 |
Return metric (% CAGR, Screener) | 1 year |
Stock price CAGR | -3 |
Capital Markets
| Metric | Astec | Dhanuka | UPL | PI Industries | Sumitomo Chem. India | Sharda Cropchem |
|---|---|---|---|---|---|---|
P/E (x) | — | 19.6 | 56.4 | 31.4 | 55.2 | 16.9 |
P/B (x) | 4.05 | 4.15 | 1.73 | 5.12 | 9.61 | 2.06 |
EV/EBITDA (x) | — | 13.0 | 9.2 | 19.5 | 37.1 | 7.3 |
Debt/equity (x) | 1.15 | 0.04 | 1.02 | 0.02 | 0.02 | 0.01 |
Astec Valuation Details
| Astec valuation (derived, Oct 2026) | Value |
|---|---|
Enterprise value (INR Cr) | ~2,022 (market cap 1,583 + FY26 debt 449 − cash ~10) |
EV / TTM sales (x) | ~4.6 |
EV / TTM EBITDA (x) | NM (TTM EBITDA near zero) |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
ICRA | Long-term fund-based (CC ₹283 crore, TL ₹100 crore) | [ICRA]AA- | Negative | 24 Mar 2026 |
ICRA | NCD ₹50 crore | [ICRA]AA- | Negative | 24 Mar 2026 |
ICRA | Short-term non-fund-based ₹335 crore | [ICRA]A1+ | — | 24 Mar 2026 |
ICRA | Commercial paper ₹300 crore | [ICRA]A1+ | — | 24 Mar 2026 |
India Ratings & Research | NCDs | IND AA- | Not captured | Jun 2026 |
Moody's / S&P / Fitch (international) | — | Not rated | — | — |
Maturity Item Details
| Maturity item | Amount (INR Cr) | Due |
|---|---|---|
NCD (INE563J08023, 8.90%, unsecured) | 49 | 25 Mar 2027 |
Total long-term repayments in FY27 (incl. NCD) | ~90 | FY27 (to be refinanced via fresh NCDs / GAVL ICDs per ICRA) |
Term loan (rated limit) | 100 | Final maturity 30 Apr 2028 |
Commercial paper | 50–100 per month rollover | Rolling, ≤1 year |
Undrawn working-capital buffer | ~317 | Available (Dec 2025) |
Analyst Conclusions
Management guidance. No numeric guidance. The Chair expects industry normalisation over the medium term; management attributes recent gains to product mix, margins in both categories, and capacity utilisation. ICRA expects recovery momentum to continue with margins below historic peaks.
Consensus growth expectations. No reliable current consensus available (see 21.3).
Bull case
-
Operating leverage is already visible. EBITDA swung from −₹60.6 crore (FY25) to +₹0.5 crore (FY26) on just ₹67 crore of incremental revenue; H2 FY26 EBITDA of ₹16.6 crore annualises to well above breakeven. A return toward FY22-like revenue (₹600+ crore) on a ₹45 crore depreciation and ₹35 crore interest base could restore meaningful profits.
-
Structural trade tailwinds. The India–China tariff differential in the US and China's VAT rebate removal on technicals directly improve Astec's competitiveness in its core export markets.
-
Parent backstop and optionality. GAVL's ₹200 crore infusion, 67% stake, ICD support and the re-alignment under Godrej Chemicals' CEO reduce solvency risk and create potential strategic upside.
Bear case
-
Cash, not EBITDA, is the problem. FY26 operating cash flow was −₹81 crore with debtor days at 202; until receivables normalise, debt will not fall organically.
-
CDMO lumpiness and opacity. CDMO revenue fell 42% YoY in Q1 FY27; with no disclosed pipeline, customer count or contract tenure, investors cannot underwrite recovery durability.
-
Valuation already discounts recovery. At ~4x book and ~4.6x EV/sales for a loss-making company with Negative-outlook credit, downside risk is significant if H2 FY27 fails to replicate H2 FY26.
Catalysts and monitorables (next 12 months)
26 Oct 2026: Q2 FY27 results — CDMO recovery vs Q2 FY26's ₹13.6 crore trough; EBITDA trajectory.
-
H2 FY27 seasonality: whether Q3–Q4 FY27 exceed H2 FY26's ₹16.6 crore EBITDA.
-
Receivables and operating cash flow at H1 FY27 balance sheet.
-
Refinancing of the ₹49 crore NCD due March 2027 and the ICRA surveillance review (~March 2027) — any outlook change to Stable.
-
RPT volumes with GAVL/GIL against approved limits.
-
Any corporate-action announcement by the parent (unconfirmed; monitor exchange disclosures).
-
Chinese triazole pricing and US tariff policy.
-
New molecule commercialisation from the Rabale R&D centre.
Analyst verdict
Astec LifeSciences is a classic cyclical-plus-transition story whose cycle appears to have turned but whose transition remains unproven. The evidence of trough-passing is credible: revenue recovered 17.5% in FY26, legacy inventory has been flushed (inventory turnover more than doubled from FY24), EBITDA has been non-negative for four consecutive quarters, and the rights issue removed the immediate solvency overhang by cutting debt/equity from 2.36x to 1.15x. Industry data — the end of global destocking, Indian tariff advantages in the US and higher Chinese export costs — supports continued volume recovery.
What remains unproven is whether Astec can convert recovery into durable returns on capital. The CDMO business, now over half of revenue, is strategically correct but operationally erratic, and management provides almost none of the disclosure (pipeline, customer count, contract tenure, R&D spend) that investors routinely receive from larger Indian CDMO peers. Working capital is the other weak link: a 263-day cash conversion cycle means each rupee of growth absorbs cash, and FY26's −₹81 crore operating cash flow illustrates the problem even in a recovery year. Credit agencies have rightly retained a Negative outlook.
The decisive variable is the parent. Godrej Agrovet's steadily rising stake, its ₹200 crore rights subscription and the April 2026 appointment of the Godrej Chemicals CEO as chair signal strategic commitment; Astec's credit and liquidity rest substantially on that support. For equity holders, however, the current valuation (~4x book, ~4.6x EV/sales, loss-making) already embeds a meaningful recovery and arguably some corporate-action optionality.
Verdict: Fundamentally improving but speculative. The risk–reward is balanced-to-unfavourable at current prices for fundamentals-driven investors; conviction would require two or three consecutive quarters of positive PAT, normalising receivables and greater CDMO disclosure. Credit investors are better protected than equity holders, given parental backing.
SOURCES REGISTER (primary and secondary references used)
-
NSE/BSE filings: Q1 FY27 press release (31 Jul 2026) — nsearchives.nseindia.com/corporate/ASTEC_31072026203640_BSENSEPRESSRELEASE31072026.pdf
-
Q3 FY26 press release (30 Jan 2026) — nsearchives.nseindia.com/corporate/ASTEC_30012026204330_BSENSEPRESSRELEASE30012025.pdf
-
Q4 FY26 press release (27 Apr 2026) — bseindia.com/xml-data/corpfiling/AttachHis/4d58e25a-b30c-409b-9012-adcb222412f4.pdf
-
Q2 FY25 press release (25 Oct 2024) — bseindia.com (corpfiling cc8662e9)
-
Integrated governance filing (30 Apr 2026) — nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_GOVERNANCE_154562_30042026115550_iXBRL_WEB.html
-
Clean Max Andes divestment intimation (9 Mar 2026) — nsearchives.nseindia.com/corporate/ASTEC_09032026193323_BSENSECleanmax.pdf
-
NCD disclosure Annex XIV-B (25 Apr 2026) — nsearchives.nseindia.com/content/debt/WDM/ASTEC_25042026113325_Disclosure_XIV-B.pdf
-
Anurag Roy resignation (23 Sep 2024) and director-change intimation (29 Aug 2025) — BSE/NSE
-
ICRA rating rationale, 24 Mar 2026 — icra.in/Rating/GetRationalReportFilePdf?id=141823; earlier rationales 25 Mar 2025, 7 Aug 2024, Sep 2017
-
ICRA Indian Agrochemical Industry reports (Apr 2025; Feb 2026)
-
SEBI open offer documents (Aug 2015; Apr–Dec 2024)
-
Screener.in consolidated financials and shareholding — screener.in/company/ASTEC/consolidated/
-
Value Research key ratios and peer comparison; Pocketful peer multiples; Simply Wall St; TipRanks; Tracxn
-
Rights issue details: Chittorgarh, FilingReader, Zerodha TradingQnA
-
Leadership transition coverage: Reuters via Stockopedia; Chemical Weekly; The Machine Maker; Board Stewardship
-
Peer results: PI Industries FY26 presentation; Rallis India FY26 press release; India Pesticides FY26 coverage
-
Market data: AgbioInvestor via AgriBusiness Global; S&P Global via Chemical Week; Rubix Data Sciences; Crisil Ratings via Outlook Business
-
Company PR Newswire release (16 Jan 2026); R&D centre launch coverage (Apr 2023)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role / category | Board since | Age (DOB) | Background |
|---|---|---|---|---|
Vishal Sharma | Chairperson; Non-Executive, Non-Independent | 13 Apr 2026 | — | Executive Director & CEO (Chemicals), Godrej Industries Ltd |
Arijit Mukherjee | Executive Director & Chief Operating Officer | ED from 13 Apr 2026 (term to 12 Apr 2029); COO since 2016 | — | 20+ years in agri-inputs; with Godrej Agrovet since 2005 in sales and marketing operations; oversees manufacturing and B2B/CDMO business |
Burjis N. Godrej | Non-Executive, Non-Independent | 25 Jul 2022 | 33 (14 Dec 1992) | Executive Director, Godrej Agrovet; Astec MD until 13 Apr 2026; GAVL Chairperson from 14 Aug 2026 |
Ashok V. Hiremath | Non-Executive, Non-Independent (founder) | 25 Jan 1994 | 71 (31 May 1955) | Founder-promoter; chairs Risk Management Committee; member of Audit Committee |
Sunil Kataria | Non-Executive, Non-Independent | 1 Sep 2025 | 58 (7 May 1968) | CEO & MD (designate at appointment), Godrej Agrovet; formerly with Godrej Consumer Products; chairs Stakeholders Relationship Committee |
R. R. Govindan | Independent | 30 Jan 2020 | 72 (13 Aug 1954) | Chairs Audit Committee and Nomination & Remuneration Committee |
Nandkumar Dhekne | Independent | 18 Dec 2020 (re-appointed 18 Dec 2025) | 69 (2 Sep 1957) | Member, Stakeholders Relationship Committee |
Anjali Rajesh Gupte | Independent | 18 Dec 2020 (re-appointed 18 Dec 2025) | 56 (3 Sep 1970) | Member, Audit and NRC |
Ganapati D. Yadav | Independent | 17 Sep 2024 | 74 (14 Sep 1952) | Eminent chemical engineer (widely reported former Vice-Chancellor, ICT Mumbai); six listed directorships |
Mathew Eipe | Independent | 13 Apr 2026 (term to 6 Jun 2027) | — | Joined Godrej Soaps in 1977; ED & President (Chemicals), Godrej Industries from 2001 until retirement in 2013; Independent Director of Godrej Industries |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Since | Notes |
|---|---|---|---|
Arijit Mukherjee | ED & COO | COO 2016; ED Apr 2026 | Basic salary range ₹35–42 lakh p.a. plus allowances, variable pay, ESOPs and retention payouts (postal ballot notice, June 2026) |
Deepak Jawaharlal Ochani | Chief Financial Officer | 1 Apr 2026 | Chartered Accountant |
Tejashree Pradhan | Company Secretary & Compliance Officer | — | FCS 7167 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
3 May 2024 | CFO K. Suryanarayan resigns | Appointed May 2023; one-year tenure |
4 Oct 2024 | Independent Director Dr. B. N. Vyas resigns | Cited advancing age |
25 Oct 2024 | CEO & WTD Anurag Roy exits | Had been re-appointed for 3 years from July 2024; no material reasons cited |
1 Apr 2025 | Burjis Godrej re-appointed (as MD, per governance filing) | Led the company through recovery |
31 Aug 2025 | Balram Singh Yadav (NED) resigns | Superannuation from Godrej Agrovet |
1 Sep 2025 | Sunil Kataria joins board | GAVL CEO-designate |
6 Mar 2026 | CFO Mugdha Khare exits | Resignation announced 30 Jan 2026 |
1 Apr 2026 | Deepak Ochani becomes CFO | Planned succession |
13 Apr 2026 | Nadir Godrej retires as Chair; Vishal Sharma Chair; Burjis Godrej steps down as MD; Arijit Mukherjee ED; Mathew Eipe ID | Group-wide generational succession plan |
5 Jun 2026 | GM–HR Vijayalakshmi Iyer resigns | Senior management |
Shareholding Trend
| Holder category (%) | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Promoter and promoter group | 66.74 | 70.87 | 72.42 | 71.97 | 71.97 |
Foreign institutional investors | 0.53 | 0.25 | 0.00 | 0.03 | 0.02 |
Domestic institutional investors | 4.50 | 4.34 | 4.01 | 3.33 | 3.34 |
Public / others | 28.20 | 24.53 | 23.57 | 24.67 | 24.67 |
Competitive Landscape
Key Competitors
| Competitor | Overlap with Astec | Latest annual revenue (INR Cr) | Positioning vs Astec |
|---|---|---|---|
PI Industries | Agchem CSM/CDMO for innovators; process chemistry | 6,714 (FY26) | Scale leader in Indian agchem CDMO; 25% EBITDA margin; net cash |
UPL | Global generics including fungicides | Not compiled | Global generic giant; vastly larger distribution |
Rallis India (Tata) | Hexaconazole and generic technicals; B2B exports and CSM | 2,897 (FY26) | Domestic branded + B2B; record 12.5% EBITDA margin in FY26 |
India Pesticides | Fungicide/herbicide technicals for export and domestic | 1,057 (FY26) | Fast-growing peer of similar heritage; 18% EBITDA margin; EU fungicide approval |
Sharda Cropchem | Generic registrations/marketing (customer and competitor) | 5,357 (TTM) | Asset-light registrant; sources from Indian/Chinese manufacturers |
Dhanuka Agritech | Domestic formulations | 1,953 (TTM) | Branded domestic; low overlap on technicals |
Bayer CropScience (India) | Triazole fungicide formulations in India | 5,595 (TTM) | Innovator/brand owner; potential customer |
Sumitomo Chemical India | Domestic formulations and technicals | 3,245 (TTM) | MNC subsidiary; potential customer |
Chinese triazole producers (multiple) | Tebuconazole, propiconazole, difenoconazole etc. | Not compiled | Primary price-setters; source of the 2023–25 price collapse (ICRA) |
Navin Fluorine, Anupam Rasayan, SRF, Aarti Industries | Specialty-chemical CDMO for agro/pharma innovators | Not compiled | Larger CDMO platforms competing for the same innovator programmes |
Gharda Chemicals (unlisted) | Technical manufacturing for export | — | Integrated Indian technical manufacturer |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Astec LifeSciences | PI Industries | Rallis India | India Pesticides |
|---|---|---|---|---|
Revenue (INR Cr) | 448 | 6,714 | 2,897 | 1,057 |
Revenue growth YoY (%) | 17.5 | -15.8 | 8.8 | 27.6 |
EBITDA margin (%) | 0.1 | 25.0 | 12.5 | 18.0 |
Net margin (%) | -18.1 | 19.7 | 6.4 | 11.4 |
R&D intensity (% of revenue) | — | Not compiled | Not compiled | Not compiled |
Debt/equity (x) | 1.15 | ~0.02 | Not compiled | Not compiled |
“—” = not publicly disclosed.



